Dr. Reddy's Laboratories Limited (DRREDDY.BO)
| Previous close | 6,300.80 |
| Open | 6,324.00 |
| Bid | 6,266.95 x 0 |
| Ask | 6,251.45 x 0 |
| Day's range | 6,200.05 - 6,348.00 |
| 52-week range | 4,383.40 - 6,505.50 |
| Volume | |
| Avg. volume | 13,631 |
| Market cap | 1.042T |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 19.99 |
| EPS (TTM) | 313.15 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | 40.00 (0.63%) |
| Ex-dividend date | 11 Jul 2023 |
| 1y target est | 2,581.68 |
- Reuters
India's Dr Reddy's beats Q4 profit view; names new CFO
BENGALURU (Reuters) -India's generic drugmaker Dr Reddy's Laboratories reported fourth-quarter profit above expectations on Tuesday on higher U.S. and Europe sales, and appointed its new chief financial officer. M V Narasimham, who is currently the deputy CFO, will take over the role from Parag Agarwal, who held the post since 2020 and will retire on July 31. The company's U.S. sales have been boosted by persistently strong demand for Lenalidomide, a generic version of Bristol-Myers Squibb's blockbuster cancer drug Revlimid, which was launched in 2022.
Business WireDr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
GlobeNewswirePharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
